Unintended Consequences of Coverage Laws Targeting Cancer Drugs

Abstract

Get full access to this article

View all access options for this article.

References

D. W.

Light and

Lexchin , “Why Do Cancer Drugs Get Such an Easy Ride? Rushed Approvals Result in a Poor Deal for Both Patients and Cancer Research,” BMJ (Online) 350, no. 8007 (2019), available at <https://doi.org/10.1136/bmj.h2068> (last visited Sept. 14, 2020).

Leopold ,

R. L.

Haffajee ,

C. Y.

Lu , and

A. K.

Wagner , “The Complex Cancer Care Coverage Environment – What Is the Role of Legislation? A Case Study from Massachusetts,” The Journal of Law, Medicine & Ethics 48, no. 3 (2020): 538-551.

T. E.

MacLeod ,

A. H.

Harris , and

Mahal , “Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers,” The Patient - Patient-Centered Outcomes Research 9, no. 3 (2016): 201–22, available at <https://doi.org/10.1007/s40271-015-0139-7> (last visited Sept. 14, 2020).

A. D.

Zhang ,

Puthumana ,

N. S.

Downing ,

N. D.

Shah ,

H. M.

Krumholz , and

J. S.

Ross , “Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017,” JAMA Network Open 3, no. 4 (2020): e203284, available at <https://doi.org/10.1001/jamanetworkopen.2020.3284> (last visited Sept. 14, 2020).

M. E.

Blume-Kohout and

Sood , “Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development,” Journal of Public Economics 97, no. 1 (2013): 327–36, available at <https://doi.org/10.1016/j.jpubeco.2012.10.003> (last visited Sept. 14, 2020).

Aitken ,

Kleinrock ,

Nass , and

Simorellis , “Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications,” available at <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019> (last visited August 28, 2020.)

Hernandez ,

San-Juan-Rodriguez ,

C. B.

Good , and

W. F.

Gellad , “Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018,” JAMA 323, no. 9 (2020): 854–62, available at <https://doi.org/10.1001/jama.2020.1012> (last visited Spet. 14, 2020).

S. B.

Dusetzina ,

H. A.

Huskamp , and

N. L.

Keating , “Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019,” JAMA 321, no. 20 (2019): 2025–27, available at <https://doi.org/10.1001/jama.2019.4492> (last visited Sept. 14, 2020).

B. D.

Sommers and

A. S.

Kesselheim , “Massachusetts’ Proposed Medicaid Reforms — Cheaper Drugs and Better Coverage?” New England Journal of Medicine 378, no. 2 (2018): 109–11, available at <https://doi.org/10.1056/NEJMp1714824> (last visited Sept. 14, 2020).

10.

J. D.

Chambers ,

D. D.

Kim ,

E. F.

Pope ,

J. S.

Graff ,

C. L.

Wilkinson , and

P. J.

Neumann , “Specialty Drug Coverage Varies Across Commercial Health Plans In The US,” Health Affairs 37, no. 7 (2018): 1041–47, available at <https://doi.org/10.1377/hlthaff.2017.1553> (last visited Sept. 14, 2020).

11.

Wieseler ,

McGauran , and

Kaiser , “New Drugs: Where Did We Go Wrong and What Can We Do Better?” BMJ 366, no. 8207 (2019): l4340, available at <https://doi.org/10.1136/bmj.l4340> (last visited Sept. 14, 2020).

12.

A. D.

Stern ,

Pietrulla ,

Herr ,

A. S

Kesselheim , and

Sarpatwari , “The Impact of Price Regulation on the Availability of New Drugs in Germany,” Health Affairs 38, no. 7 (2019): 1182–87, available at <https://doi.org/10.1377/hlthaff.2018.05142> (last visited Sept. 14, 2020).

13.

Dakin ,

Devlin ,

Feng ,

Rice ,

O ’Neill, and

Parkin , “The Influence of Cost-Effectiveness and Other Factors on Nice Decisions,” Health Economics 24, no. 10 (2015): 1256–1271, available at <https://doi.org/10.1002/hec.3086> (last visited Sept. 14, 2020).

14.

Jack

, “Which Way Now for the Cancer Drugs Fund?” BMJ 349, no. 7974 (2014): g5524.

15.

Wenzl and

Chapman , “Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going Forward,” OECD Health Working Papers, no. 115 (2019), available at <https://doi.org/10.1787/6e5e4c0f-en> (last visited Sept. 14, 2020).

16.

Aggarwal ,

Fojo ,

Chamberlain ,

Davis , and

Sullivan , “Do Patient Access Schemes for High-Cost Cancer Drugs Deliver Value to Society?-Lessons from the NHS Cancer Drugs Fund,” Annals of Oncology 28, no. 8 (2017): 1738–1750, available at <https://doi.org/10.1093/annonc/mdx110> (last visited Sept. 14, 2020).

17.

H. P.

Macdonald and

Goldacre , “Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-Sectional Analysis On Publicly Accessible Documentation,” MedRxiv (March 2020), available at <https://doi.org/10.1101/2020.03.06.19014944> (last visited Sept. 14, 2020).

18.

See Wenzl and Chapman, supra note 15.